Colgate-Palmolive (NYSE:CL) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Tuesday.

According to Zacks, “Colgate, which has lagged the industry in the past six months, witnessed strained margins lately. This stemmed from increased raw material and packaging costs, as well as higher advertising expenses. Further, it anticipates the aforementioned costs to persist and impact margins in 2017. Additionally, the company perked up its costs guidance related to charges arising from the expansion and extension of the Global Growth and Efficiency Program through Dec 31, 2019. This is also likely to put near-term pressure on the results.  Nonetheless, the company is encouraged by the progress and prospects from this program, with additional savings anticipated from this recent expansion. Also, the company with a meet or beat earnings track record, has been gaining from its robust brands portfolio and constant innovations. Colgate’s shareholder-friendly moves also remain noteworthy. Estimates have been stable lately ahead of fourth-quarter earnings.”

CL has been the subject of several other reports. SunTrust Banks upgraded Colgate-Palmolive from a “hold” rating to a “buy” rating and raised their price target for the company from $65.00 to $85.00 in a report on Wednesday, October 11th. Societe Generale downgraded Colgate-Palmolive from a “hold” rating to a “sell” rating and set a $66.00 price target for the company. in a report on Wednesday, November 29th. They noted that the move was a valuation call. Citigroup reduced their price objective on Colgate-Palmolive from $76.00 to $75.00 and set a “neutral” rating for the company in a report on Thursday, November 2nd. Stifel Nicolaus set a $73.00 price objective on Colgate-Palmolive and gave the stock a “hold” rating in a report on Sunday, October 29th. Finally, Royal Bank of Canada reiterated a “hold” rating and issued a $74.00 price objective on shares of Colgate-Palmolive in a report on Sunday, October 8th. Three investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and five have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $76.33.

Colgate-Palmolive (NYSE CL) opened at $74.52 on Tuesday. Colgate-Palmolive has a twelve month low of $63.43 and a twelve month high of $77.27. The company has a current ratio of 1.23, a quick ratio of 0.92 and a debt-to-equity ratio of 24.42. The firm has a market capitalization of $65,440.00, a price-to-earnings ratio of 25.78, a PEG ratio of 3.39 and a beta of 0.81.

Colgate-Palmolive (NYSE:CL) last issued its quarterly earnings results on Friday, October 27th. The company reported $0.73 earnings per share for the quarter, meeting the consensus estimate of $0.73. Colgate-Palmolive had a return on equity of 2,782.56% and a net margin of 15.10%. The firm had revenue of $3.97 billion during the quarter, compared to the consensus estimate of $3.94 billion. During the same period last year, the company earned $0.73 earnings per share. The company’s revenue was up 2.8% on a year-over-year basis. sell-side analysts anticipate that Colgate-Palmolive will post 2.88 EPS for the current fiscal year.

In other Colgate-Palmolive news, COO Justin Skala sold 126,393 shares of the business’s stock in a transaction dated Thursday, November 9th. The stock was sold at an average price of $72.97, for a total transaction of $9,222,897.21. Following the completion of the sale, the chief operating officer now directly owns 262,361 shares in the company, valued at approximately $19,144,482.17. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Stephen I. Sadove sold 20,780 shares of the business’s stock in a transaction dated Monday, November 6th. The shares were sold at an average price of $70.52, for a total value of $1,465,405.60. Following the sale, the director now owns 36,268 shares of the company’s stock, valued at $2,557,619.36. The disclosure for this sale can be found here. Insiders sold a total of 181,048 shares of company stock valued at $13,168,995 over the last quarter. 1.02% of the stock is owned by corporate insiders.

Institutional investors have recently added to or reduced their stakes in the business. Pacer Advisors Inc. lifted its position in shares of Colgate-Palmolive by 8.4% during the 2nd quarter. Pacer Advisors Inc. now owns 20,224 shares of the company’s stock valued at $1,499,000 after buying an additional 1,566 shares in the last quarter. Alliancebernstein L.P. lifted its position in shares of Colgate-Palmolive by 4.2% during the 1st quarter. Alliancebernstein L.P. now owns 1,899,356 shares of the company’s stock valued at $139,014,000 after buying an additional 77,414 shares in the last quarter. Israel Discount Bank of New York purchased a new position in shares of Colgate-Palmolive during the 1st quarter valued at about $1,349,000. Principal Financial Group Inc. lifted its position in shares of Colgate-Palmolive by 0.6% during the 1st quarter. Principal Financial Group Inc. now owns 1,271,008 shares of the company’s stock valued at $93,025,000 after buying an additional 7,905 shares in the last quarter. Finally, Personal Capital Advisors Corp lifted its position in shares of Colgate-Palmolive by 5.8% during the 2nd quarter. Personal Capital Advisors Corp now owns 394,028 shares of the company’s stock valued at $29,209,000 after buying an additional 21,456 shares in the last quarter. Institutional investors and hedge funds own 72.84% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Colgate-Palmolive (CL) Rating Lowered to Sell at Zacks Investment Research” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another site, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/12/21/colgate-palmolive-cl-rating-lowered-to-sell-at-zacks-investment-research.html.

Colgate-Palmolive Company Profile

Colgate-Palmolive Company (Colgate) is a consumer products company. The Company operates in two product segments: Oral, Personal and Home Care, and Pet Nutrition. The Oral, Personal and Home Care product segment is operated through five geographic segments, which include North America, Latin America, Europe, Asia Pacific and Africa/Eurasia.

Analyst Recommendations for Colgate-Palmolive (NYSE:CL)

Receive News & Ratings for Colgate-Palmolive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive and related companies with MarketBeat.com's FREE daily email newsletter.